Global Hypertrophic Cardiomyopathy Therapeutics Market to reach US$1.4 bn by 2023:Transparency Market Research

Albany, NY, Nov. 9, 2015 (GLOBE NEWSWIRE) -- Transparency Market Research has published a new market report titled, "Hypertrophic Cardiomyopathy Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends, and Forecast, 2015 - 2023." According to the report, the global hypertrophic cardiomyopathy therapeutics market was valued at US$1.2 bn in 2014 and is expected to expand at a CAGR of 1.4% from 2015 to 2023 to reach US$1.4 bn by 2023.

Browse the full report at http://www.transparencymarketresearch.com/hypertrophic-cardiomyopathy-therapeutics-market.html

The beta adrenergic blocking agent segment is projected to expand at the second highest CAGR during the forecast period from 2015 to 2023, as it is the first choice of treatment for obstructive and non-obstructive HCM. The antiarrhythmic and anticoagulants drug segments held the third and fourth largest shares of the global market in terms of revenue in 2014. However, rising technological upgrade of devices such as defibrillators and pacemakers could restraint market growth. The hypertrophic cardiomyopathy therapeutics market is likely to be driven by increase in sedentary lifestyle among the young population and rise in obese population.

Get PDF Sample Brochure of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=7553

The report provides detailed analysis of current and emerging drugs for hypertrophic cardiomyopathy (HCM), bifurcating them based on type of drug class. Drugs have been analyzed by segments such as beta adrenergic blocking agents, calcium channel blocker, antiarrhythmic agents, and anticoagulants. Calcium channel blockers was the largest segment of the global hypertrophic cardiomyopathy therapeutics market in 2014. The segment dominated the market due to high price of calcium channel blockers in comparison to other drugs.

Browse Press Release: http://www.transparencymarketresearch.com/pressrelease/hypertrophic-cardiomyopathy-therapeutics-market.htm

The beta adrenergic blocking agent segment is projected to expand at the second highest CAGR during the forecast period from 2015 to 2023, as it is the first choice of treatment for obstructive and non-obstructive HCM. The antiarrhythmic and anticoagulants drug segments held the third and fourth largest shares of the global market in terms of revenue in 2014. However, rising technological upgrade of devices such as defibrillators and pacemakers could restraint market growth. The hypertrophic cardiomyopathy therapeutics market is likely to be driven by increase in sedentary lifestyle among the young population and rise in obese population.

Sanofi S.A. and Pfizer, Inc. dominated the global hypertrophic cardiomyopathy therapeutics market in 2014. AstraZeneca plc, Concordia Healthcare Corp., Merck & Co., Inc., Teva Pharmaceuticals Limited, Mylan N.V., Gilead Sciences, Inc., and Novartis AG are the other major companies operating in the global hypertrophic cardiomyopathy therapeutics market.

The global hypertrophic cardiomyopathy therapeutics market has been segmented as follows:

Global Hypertrophic Cardiomyopathy Therapeutics Market, by Drug Class

  • Beta Adrenergic Blocking Agents
  • Calcium Channel Blocker
  • Antiarrhythmic Agents
  • Anticoagulants

Global Hypertrophic Cardiomyopathy Therapeutics Market, by Geography

  • North America
  • U.S.
  • Canada
  • Europe
  • U.K.
  • Germany
  • Rest of Europe
  • Asia Pacific
  • India
  • Japan
  • Rest of Asia Pacific
  • Rest of the World (RoW)
  • Latin America
  • Middle East
  • Africa

Other Research Reports By Transparency Market Research:

1. Spinal Muscular Atrophy Phase 3 Candidate ISIS-SMNRx Expected to Reach USD 0.47 Billion in Sales in the U.S

According to a new market report published by Transparency Market Research, "Spinal Muscular Atrophy Market: Pipeline Assessment, Size, Growth, Trends, and Forecast, 2015 - 2023" the spinal muscular atrophy market phase three candidate ISIS-SMNRx is expected to generate total revenue of USD 0.47 billion by 2023.

Get Sample Research Report:

http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=7187

2. Thyroid Gland Disorders Treatment Market in Asia Pacific expected to grow at highest CAGR of 3.6% in future

According to a new market research report published by Transparency Market Research "Thyroid Gland Disorders Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023" the global thyroid gland disorders treatment market was valued at US$1.8 bn in 2014 and is estimated to reach a market value of US$2.4 bn in 2023 expanding at a CAGR of 3.1% from 2015 to 2023.

Get Sample Research Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3113

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company's exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR's data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

CONTACT: Mr. Nachiket Ghumare 90 State Street, Suite 700 Albany, NY 12207 Tel: +1-518-618-1030 USA - Canada Toll Free: 866-552-3453 Email: sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com/

Source:Transparency Market Research